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Abstract
Objective: The International Association of Diabetes and Pregnancy Study Groups (IADPSG) recently
proposed new criteria for diagnosing gestational diabetes mellitus (GDM). We compared prevalence
rates, risk factors, and the effect of ethnicity using the World Health Organization (WHO) and modiﬁed
IADPSG criteria.
Methods: This was a population-based cohort study of 823 (74% of eligible) healthy pregnant women,
of whom 59% were from ethnic minorities. Universal screening was performed at 28G2 weeks of
gestation with the 75 g oral glucose tolerance test (OGTT). Venous plasma glucose (PG) was measured
on site. GDM was diagnosed as per the deﬁnition of WHO criteria as fasting PG (FPG) R7.0 or 2-h PG
R7.8 mmol/l; and as per the modiﬁed IADPSG criteria as FPG R5.1 or 2-h PG R8.5 mmol/l.
Results: OGTT was performed in 759 women. Crude GDM prevalence was 13.0% with WHO (Western
Europeans 11%, ethnic minorities 15%, PZ0.14) and 31.5% with modiﬁed IADPSG criteria (Western
Europeans 24%, ethnic minorities 37%, P! 0.001). Using the WHO criteria, ethnic minorityorigin was
an independent predictor (South Asians, odds ratio (OR) 2.24 (95% conﬁdence interval (CI) 1.26–3.97);
Middle Easterners, OR 2.13 (1.12–4.08)) after adjustments for age, parity, and prepregnant body mass
index(BMI).ThisincreasedORwasunapparentafterfurtheradjustmentsforbodyheight(proxyforearly
life socioeconomic status), education and family history of diabetes. Using the modiﬁed IADPSG criteria,
prepregnant BMI (1.09 (1.05–1.13)) and ethnic minorityorigin (South Asians, 2.54 (1.56–4.13)) were
independent predictors, while education, body height and family history had little impact.
Conclusion: GDM prevalence was overall 2.4-times higher with the modiﬁed IADPSG criteria compared
with the WHO criteria. The new criteria identiﬁed many subjects with a relatively mild increase in FPG,
strongly associated with South Asian origin and prepregnant overweight.
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Introduction
Gestational diabetes mellitus (GDM), deﬁned as any
degree of glucose intolerance with onset or ﬁrst
recognition during pregnancy, was ﬁrst described
about half a century ago (1). The diagnostic criteria
for GDM were initially developed to predict future
diabetes in the mother, although its link with
macrosomia was recognized. Today, a variety of
screening procedures and diagnostic criteria are
used (2). This lack of a standardized approach hampers
the understanding, research and clinical care of GDM
(3). Prevalence rates of GDM in population-based
studies range from 1 to 22% (4). This diversity also
reﬂects differences between the study populations in
ethnic origin and age, and an increasing prevalence
associated with the global epidemic of obesity and
diabetes (4).
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and Pregnancy Study Groups (IADPSG) proposed
new criteria for GDM (5) based on the ﬁndings from
the Hyperglycaemia and Adverse Pregnancy Outcome
(HAPO) study (6). The HAPO study showed a
continuous and graded relationship between maternal
glycemia and adverse fetal outcomes. The cutoff values
in the new criteria were set to reﬂect an odds ratio (OR)
of at least 1.75 for an adverse fetal outcome, deﬁned
as above the 90th percentile for birth weight, cord
C-peptide or percent body fat compared with subjects
having glucose values equal to or below the mean value
in the full cohort, although other ORs were discussed.
The proposed diagnostic cutoff values for glucose in
the IADPSG criteria are slightly lower than those in the
criteria that are currently most widely used in North
America (3). Furthermore, one single glucose value
above the cutoff value (fastingor during the oral glucose
tolerance test (OGTT)) is sufﬁcient to diagnose GDM, as
opposed to two elevated glucose values. Universal
instead of selective screening is recommended (5).I n
Europe, either the World Health Organization (WHO)
criteria based on the cutoff values for diabetes and
impaired glucose tolerance outside pregnancy (7) or the
slightly modiﬁed European Association for the Study of
Diabetes (EASD) criteria (8) are used most frequently
when diagnosing GDM. Compared with these criteria,
the IADPSG criteria’s glucose cutoff values are lowered
for the fasting and raised for the post-OGTT values.
In many parts of the world, ethnic minority groups,
which are often socially disadvantaged (9),a r e
disproportionally more affected by type 2 diabetes (10)
and GDM (11). The present population-based STORK
Groruddalen Study was conducted in the district of Oslo,
Norway, covering 82 000 inhabitants, of whom 40%
have an ethnic minority background (12). This study
was aimed to determine the prevalence of GDM and its
risk factors with the WHO (7) and the IADPSG criteria,
slightly modiﬁed due to lack of 1-h glucose values (5)
overall, in the largest ethnic groups. Furthermore, we
wanted to assess the association between ethnic origin
and these criteria after adjusting for covariates and
discuss the implications of the proposed criteria for
public health preventive strategies.
Design and methods
Design, study population and data collection
This population-based cohort study was conducted at
three public Child Health Clinics in Groruddalen, Oslo,
Norway (12). Antenatal care for pregnant women in
Norway is carried out in primary care, either at the
public Child Health Clinic alone or in combination with
the general practitioner (GP), or by the GP alone (13).
Groruddalen covers afﬂuent as well as more deprived
residential areas and has a population with a diverse
socioeconomic status. The majority (75–85%) of
pregnant women residing in this area attend the Child
Clinics for antenatal care.
From May 6, 2008 to May 15, 2010, 823 (74% of
eligible) women were included. All information material
and questionnaires were translated to Arabic, English,
Sorani, Somali, Tamil, Turkish, Urdu and Vietnamese,
and quality controlled by bilingual health professionals.
Women were eligible if they i) lived in the districts,
ii)plannedtogivebirthatone ofthe two studyhospitals,
iii) were !20 weeks pregnant, iv) could communicate
in Norwegian or any of the above speciﬁed languages
and v) were able to give a written consent to participate.
Women with pregestational diabetes or other diseases
necessitating intensive hospital follow-up during preg-
nancy were excluded. The Regional Ethics Committee
and the Norwegian Data Inspectorate approved the
study protocol.
We have previously published a paper in which the
study population is described in detail (12). At baseline,
participants were representative for women attending
the Child Health Clinics with respect to ethnicity and
age. A slight selection toward lower parity (South
Asians) and age (Africans) was found. The study
methods have been presented elsewhere (12). In short,
data from questionnaires, anthropometric measure-
ments and venous fasting blood samples drawn after
an overnight fast, were collected by specially trained
midwives at !20 and at 28G2 weeks of gestation.
All staff members were certiﬁed after extensive edu-
cation and on-site supervision and were assisted by
professional translators when needed. Collected data
included demographic and socioeconomic factors
(education, employment and body height), family
history of diabetes, medical and obstetric history and
information related to the pregnancy. Body height was
measured to the nearest 0.1 cm (ﬁxed stadiometer
checked against a standard meter) and body weight
was measured to the nearest 0.1 kg using a Tanita-BC
418 MA scale (Tanita Corp., Tokyo, Japan). Self-
reported prepregnant body weight correlated strongly
with weight at inclusion (rZ0.97, P!0.001, mean
difference: 2.0 kg) and was used to calculate prepreg-
nant body mass index (BMI).
Ethnicity may be deﬁned as the social group a person
belongs to, which implies shared culture, history,
geographical origins, language, lifestyle factors, and
physical, genetic and other factors (14). In this study,
ethnic origin was deﬁned by the participant’s countryof
birth or the participant’s mother’s country of birth if
the participant’s mother was born outside of Europe or
North America. Women with ethnic origin from Eastern
Europe, Asia, Africa and South America and Central
America are referred to as ethnic minority women. The
reference group participants, Western Europeans, were
born in Norway (93.6%), Sweden or Denmark (3.2%),
or other Western European countries (3.2%, includes
North America, nZ3).
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A 75 g OGTT was performed at 28 weeks of gestation
after an overnight fast. GDM was diagnosed with the
WHO criteria (fasting plasma glucose (FPG) R7.0 or
2-h PG R7.8 mmol/l (7)) and the slightly modiﬁed
IADPSG criteria (FPG R5.1 or 2-h PG R8.5 mmol/l
(5)), as 1-h glucose values were not available. For
the diagnosis and handling of the GDM cases during
the study, the WHO criteria were used. In accordance
with the national guidelines (15), women with
FPG R7.0 mmol/l or 2-h PG R9.0 mmol/l were
referred to secondary care and those with 2-h PG
7.8–9.0 mmol/l were referred to their GP, after lifestyle
advice had been given.
Glucose was measured on site (within 5 min after
vein puncture) in venous EDTA blood according to a
standardized protocol, using a patient-near method
(HemoCue 201C, Angelholm, Sweden) calibrated
for plasma. This method was preferred to: i) avoid
preanalytical glucose reductions due to glycolysis
during shipment to the laboratory; and ii) receive
immediate results to allow optimal patient information
and necessary actions when GDM was diagnosed.
The total system variation at 2.0 and 7.0 mmol/l was
1 S.D.Z0.21 and 0.25 mmol/l respectively. The same
batch number of cuvettes and controls (run weekly, all
within 1 S.D.Z0.5 mmol/l from mean) was used at the
three study sites. The three instruments were externally
validated one to two times per year against recently
drawn patient blood as controls with mean 6.7 mmol/l
(maximum 1 S.D.Z0.11 mmol/l) and three controls
with mean 3.0, 7.0 and 11.0 mmol/l (maximum 1
S.D.Z0.20 mmol/l for all).
The on-site measured glucose values were checked
in a large subgroup of samples against the glucose
values measured by standard clinical chemistry labo-
ratory (Vitros 5.1 FS, Ortho Clinical Diagnostics,
Rochester, MN, USA, slide adapted colorimetric
method at the Department of Multidisciplinary Labo-
ratory Medicine and Medical Biochemistry, Akershus
University Hospital). For this analysis, venous blood
was drawn in gel tubes, allowed to clot for 30 min,
and thereafter stored at C4 8C until daily shipment to
the laboratory. The mean difference in glucose values
between the on-site measurements and the measure-
ments performed at the hospital laboratory for the 2-h
PG value was 0.30 mmol/l; the measurements highly
correlated with R
2Z0.913, and a linear regression
equation: 2-h PG (HemoCue)Z0.989C0.883!2-h PG
(Hospital). HbA1c was measured with HPLC (Tosoh G8,
Tosoh Corporation, normal reference range 4–6%).
When valid HemoCue FPG or 2-h PG values were
missing, glucose values from the hospital laboratory
(FPG, nZ14; 2-h PG, nZ9) or values extracted from the
medical records (FPG, nZ11; 2-h PG, nZ14) were
used. One woman started insulin treatment at 20 weeks
of gestation and OGTT was not performed at 28 weeks.
Statistical analyses
The main outcome variable was GDM. The study was
designed to be large enough to show differences in
prevalence rates of GDM with the WHO criteria between
the major ethnic groups, based on the following
assumed prevalences: Western Europeans, 5%; South
Asians, 20%; and other ethnic minority groups, 10%.
We aimed to enroll at least 800 women, which would
give w100 GDM cases (12).
Differences in characteristics between groups were
tested with t-tests and one-way ANOVA for normally
distributed continuous variables and c
2 tests for
categorical variables, and with the Mann–Whitney
test for non-normally distributed continuous data.
Pearson’s or Spearman correlation coefﬁcients were
calculated as appropriate.
Univariate and multiple logistic regression analyses
were performed to identify the effect of ethnic origin
on GDM with the WHO and modiﬁed IADPSG criteria
separately, after adjusting for covariates. In model A,
age, prepregnant BMI and parity were entered as
adjustment covariates, whereas in model B, education
and body height (used as a proxy for early life
socioeconomic status) were further added. In the ﬁnal
model C, all covariates, including ﬁrst-degree relatives
with diabetes, were entered. Interactions were tested
on the relative scale by adding into each model a cross
product term between two-by-two factors at a time.
Statistical signiﬁcance level was set to P!0.05. ORs
with 95% CI were estimated. SPSS version 18 (IBM
SPSS Statistics, NY, USA) was used.
Results
Characteristics of women
Of the 823 included women, 18 (2%) had an abortion
or delivery before the visit at 28 weeks of gestation and
33 (4%) did not attend the clinic. Of the 772 (93.8%)
women who attended the clinic at 28 weeks of
gestation, 13 were not able to complete the OGTT, and
thus the OGTT datawere available only for 759 (92.2%)
women.
Fifty-nine percent were from an ethnic minority
group, with the largest groups being composed of South
Asians (25%) and Middle Easterners (15%). Baseline
characteristics did not differ between those with and
without OGTT data. Western European women were
older, taller, had lower parity and higher education
compared with the ethnic minority women (Table 1).
Mean prepregnant BMI did not differ between Western
European and ethnic minority women, although a
considerable heterogeneity between the ethnic minority
groups was observed for several variables, such as
prepregnant BMI, parity and education, as shown
in Table 1.
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The number of women diagnosed as having GDM
with the WHO criteria and the modiﬁed IADPSG
criteria was 99 and 239 respectively, giving crude
prevalence rates of 13.0 and 31.5% respectively. The
prevalence rates in Western European (10.9%) and
ethnic minority women (14.6%) with the WHO criteria
were not signiﬁcantly different (PZ0.14), but with the
modiﬁed IADPSG criteria, the difference was highly
signiﬁcant (24 and 36.8% respectively, P!0.001;
Fig. 1, Table 2). The GDM prevalence increased 2.8
t i m e si nS o u t hA s i a na n d2 . 2t i m e si nW e s t e r n
European and Middle Eastern women (2.4 overall),
after applying the modiﬁed IADPSG criteria, compared
with the WHO criteria.
With the modiﬁed IADPSG criteria, 24.2% were
diagnosed exclusively by FPG R5.1 mmol/l, 3.3%
exclusively by 2-h PG R8.5 mmol/l, and 4.0% by
both FPG and 2-h PG above the cutoff values. FPG
R5.1 mmol/l was found in 21.4% of Western
European, 37.2% of South Asian and 35.7% of Middle
Eastern women.
Comparison of the GDM groups identiﬁed with both
the WHO and the modiﬁed IADPSG criteria (9.4%), with
the WHO criteria only (3.7%), and with the modiﬁed
IADPSG criteria only (22.1%; Table 2) revealed signi-
ﬁcant differences between the groups for age, body
height,glucoseandHbA1c(P!0.001–0.02).Thegroup
identiﬁed with the modiﬁed IADPSG criteria only had
higher BMI at 28 weeks of gestation (PZ0.05), higher
HbA1c at both visits, tended to be taller (PZ0.07) and
fewer were nulliparous (PZ0.04) compared with the
group identiﬁed with the WHO criteria only.
Effect of ethnicity
For GDM with the WHO criteria, ethnic minority origin
was an independent predictor (overall, PZ0.026;
South Asians, OR 2.24 (95% CI 1.26–3.97); Middle
Eastern women, 2.13 (1.12–4.08)) when adjusted for
age, prepregnant BMI and parity (model A; Table 3).
However, when education and body height (a proxy for
earlylifesocioeconomicstatus)wereadded(modelB),the
increased OR for ethnic minority women was eliminated.
Similar ﬁndings were made in the ﬁnal model (model C)
with additional adjustments for a family history of
diabetes. In this model, only age (OR (95% CI): 1.12
(1.06–1.18)), parity (OR (95% CI): 2.33 (1.39–3.90)),
body height (cm; OR (95% CI): 0.92 (0.88–0.96)) and
family history (1.89 (1.32–2.71)) were independently
associated with GDM, while education and prepregnant
BMI were borderline signiﬁcant predictors.
A different pattern was found when assessing
predictors for GDM with the modiﬁed IADPSG criteria.
All models revealed a signiﬁcantly increased OR for
GDM for ethnic minority women. Adjustment for
education, body height and family history of diabetes
had little impact (models B and C). In model C, only
prepregnant BMI (per unit change; OR (95% CI): 1.09
Table 1 Baseline characteristics of the total cohort stratiﬁed into Western European and ethnic minority women, and further into ethnic
origin. Data are mean (S.D.), unless otherwise stated.
Total
Western
Europe
a
Ethnic
minority
Eastern
Europe
b
South
Asia
c
East
Asia
d
Middle
East
e Somalia
Sub-Saharan
Africa/
South America
f
n (%) 759 (100.0) 313 (41.2) 446 (58.8) 42 (5.5) 188 (24.8) 39 (5.1) 112 (14.8) 35 (4.6) 30 (4.0)
Years of maternal age 29.9 (4.8) 30.9 (4.5) 29.1 (4.9) 28.7 (4.1) 28.7 (4.5) 31.0 (4.6) 29.4 (5.4) 28.5 (5.8) 29.4 (5.8)
Parity, n (%)
Nulliparous 347 (45.7) 162 (51.7) 185 (41.5) 27 (64.3) 78 (41.5) 16 (41.0) 38 (33.9) 13 (37.1) 13 (43.3)
Uniparous 261 (34.4) 116 (37.1) 145 (32.5) 12 (28.6) 62 (33.0) 16 (41.0) 39 (34.8) 5 (14.3) 11 (36.7)
Multiparous (R 2) 151 (19.9) 35 (11.2) 116 (26.0) 3 (7.1) 48 (25.5) 7 (18.0) 35 (31.3) 17 (48.6) 6 (20.0)
Educational level
g, n (%)
!10 y schooling 123 (16.3) 10 (3.2) 113 (25.3) 5 (12.2) 33 (17.6) 8 (20.5) 42 (37.5) 21 (60.0) 4 (13.3)
Secondary level, 10–12 y 297 (39.5) 95 (30.6) 202 (45.7) 14 (34.1) 94 (50.3) 16 (41.0) 50 (45.5) 11 (31.4) 17 (56.7)
University/college 333 (44.2) 206 (66.2) 127 (28.7) 22 (53.7) 60 (32.1) 15 (38.5) 18 (16.4) 3 (8.6) 9 (30.0)
Employed
g, n % 525 (70.0) 272 (87.5) 253 (57.6) 31 (75.6) 115 (62.2) 31 (79.5) 52 (46.8) 9 (26.5) 15 (51.7)
First-degree relatives
with diabetes
g, n %
194 (25.6) 40 (13.0) 154 (35.6) 8 (19.5) 88 (47.3) 6 (15.8) 42 (38.5) 6 (20.0) 4 (13.4)
Gestational week at inclusion 15 (3.4) 14 (2.3) 16 (3.9) 15 (3.1) 16 (3.9) 16 (3.9) 15 (3.3) 18 (5.5) 16 (3.8)
Body height (cm) 163.7 (6.7) 167.4 (5.6) 161.1 (6.1) 166.2 (5.8) 160.0 (5.6) 157.2 (6.1) 161.2 (5.5) 164.1 (5.8) 161.6 (6.3)
BMI prepregnant
g (kg/m
2) 24.6 (4.8) 24.6 (4.8) 24.6 (4.9) 23.8 (4.4) 23.7 (4.1) 22.3 (3.4) 25.9 (5.1) 26.8 (6.5) 26.3 (5.8)
aNorway, 93.6%; Sweden and Denmark, 3.2% and other Western Europe (includes North America nZ3), 3.2%.
bPoland, 16.7%; Russia, 14.3%; Kosovo, 14.3% and other Eastern Europe, 54.8%.
cPakistan, 62.2%; Sri Lanka, 30.9% and other South Asia, 6.9%.
dVietnam, 43.6%; Philippines, 28.2%; Thailand, 10.3% and other Eastern Asia, 17.9%.
eIraq, 30.4%; Turkey, 22.3%; Morocco, 19.6%; Afghanistan, 10.7% and other Middle East, 16.8%.
fSub-Saharan Africa, 53.3%; South/Central America, 26.7% and Nigeria, 33.3%.
gIncomplete data on the variables because of missing values for 6–19 women.
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PZ0.002; South Asians, 2.54 (1.56–4.13)) were
independently associated with GDM (education border-
line signiﬁcant).
Discussion
To our knowledge, this is the ﬁrst population-based
study comparing the prevalence of GDM with the WHO
and the proposed new IADPSG criteria (slightly
modiﬁed) in a multi-ethnic population, based on
universal screening. The main ﬁndings were the high
prevalences of GDM identiﬁed with the modiﬁed
IADPSG criteria in all ethnic groups studied and the
considerable differences between the populations ident-
iﬁed with the two criteria. With the WHO criteria, the
excess risk for GDM related to ethnic minority origin
was not apparent after adjustments for other known
risk factors. However, with the modiﬁed IADPSG
criteria, ethnic minority origin remained a signiﬁcant
predictor of GDM after adjustments for the same factors.
The prevalence of GDM with the WHO criteria in this
study, overall and in Western Europeans, is higher than
that reported in some (4), but not all (16, 17) studies
from comparable populations. Observed differences may
be attributed to secular trends for obesity, maternal age,
ethnic origin of the study population and a preference
for selective screening with lower sensitivity in most
studies (18). In addition, some studies have used slightly
modiﬁed WHO criteria (4).
In this study, there was a 2.2-to 2.8-fold increase in
the GDM prevalence for the main ethnic groups when
applying the modiﬁed IADPSG criteria and an equal
increase has been reported by others (19, 20). The
prevalence of GDM with the modiﬁed IADPSG criteria
was high, but similar high rates have been reported in
other high-risk ethnic groups (21). The prevalence in
this study was substantially higher than that in the
HAPO study (17.8%) (5); however, high-risk ethnic
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Figure 1 Crude GDM prevalence, with 95% CI, based on the WHO
and the modiﬁed IADPSG criteria for the total cohort and the main
ethnic minority groups.
Table 2 Characteristics for the gestational diabetes mellitus (GDM) groups identiﬁed by the WHO and the modiﬁed International
Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria and stratiﬁed into groups based on different diagnostic cutoff
values for GDM. Data are mean (S.D.) unless otherwise stated.
GDM GDM
Total WHO
a
Total
IADPSG
b
No GDM by
any criteria
c
WHO and
IADPSG
d
WHO
only
e
IADPSG
only
f P1 P2
n (%) 99 (13.0) 239 (31.5) 492 (64.8) 71 (9.4) 28 (3.7) 168 (22.1)
Years of maternal age 31.8 (4.8) 30.2 (5.1) 29.6 (4.7) 32.2 (4.8) 30.5 (4.6) 29.4 (5.0) !0.001 0.208
Nulliparous, n (%) 49 (59.5) 104 (43.5) 225 (45.7) 31 (43.7) 18 (64.3) 73 (43.5) 0.113 0.041
Educational level !10 years
g, n (%) 24 (24.5) 51 (21.4) 68 (14.0) 20 (28.6) 4 (14.3) 31 (18.5) 0.161 0.594
Ethnic minorities, n % 65 (65.7) 164 (68.6) 267 (54.3) 50 (70.4) 15 (53.6) 114 (67.9) 0.257 0.140
First-degreerelativeswithdiabetes
g,n(%) 39 (41.1) 75 (32.2) 109 (22.7) 29 (42.6) 10 (37.0) 46 (27.0) 0.081 0.332
Body height (cm) 161.0 (6.6) 163.1 (6.6) 164.1 (6.7) 160.8 (6.6) 161.5 (6.6) 164.0 (6.5) 0.001 0.073
BMI prepregnant
g (kg/m
2) 25.7 (5.0) 26.0 (5.6) 23.9 (4.3) 26.1 (5.3) 24.7 (4.1) 26.0 (5.8) 0.514 0.171
FPG !20 weeks gestation
g (mmol/l) 4.6 (0.5) 4.7 (0.4) 4.3 (0.4) 4.7 (0.5) 4.4 (0.3) 4.6 (0.4) 0.004 !0.001
FPG 28 weeks gestation (mmol/l) 5.2 (0.8) 5.5 (0.5) 4.5 (0.3) 5.4 (0.8) 4.6 (0.3) 5.5 (0.4) !0.001 !0.001
2-h PG 28 weeks gestation
g (mmol/l) 8.8 (0.9) 7.1 (1.6) 5.7 (1.0) 9.1 (0.9) 8.0 (0.2) 6.3 (1.0) !0.001 !0.001
HbA1c !20 weeks gestation
g (%) 5.2 (0.3) 5.3 (0.3) 5.1 (0.3) 5.3 (0.3) 5.1 (0.3) 5.3 (0.3) 0.023 0.023
HbA1c 28 weeks gestation
g (%) 5.3 (0.4) 5.3 (0.3) 5.1 (0.3) 5.4 (0.4) 5.1 (0.3) 5.3 (0.3) !0.001 0.007
Gestational week at OGTT 28 (1.5) 28 (1.2) 28 (1.3) 28 (1.5) 28 (1.3) 28 (1.1) 0.029 0.079
P values for the differencesbetween the GDM WHO and modiﬁed IADPSG, the WHO only and the modiﬁed IADPSG only (P1), and between the WHO only and
the modiﬁed IADPSG only (P2).
aTotal GDM by the WHO criteria (FPG R7.0 mmol/l and/or 2-h PG R7.8 mmol/l).
bTotal GDM by the modiﬁed IADPSG criteria (FPG R5.1 mmol/l and/or 2-h PG R8.5 mmol/l).
cThe group without GDM.
dGDM by both the WHO and the modiﬁed IADPSG criteria (FPG R5.1 mmol/l and 2-h PG R7.8).
eGDM by the WHO criteria only (FPG !5.1 mmol/l and 2-h PG 7.8–8.4 mmol/l).
fGDM by the modiﬁed IADPSG criteria only (FPG 5.1–6.9 mmol/l and 2-h PG !7.8 mmol/l).
gIncomplete data on the variables because of missing values for 1–19 women.
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In addition, the HAPO study was not population-based,
had a lower attendance rate (53.6 vs 74%), had stricter
inclusion criteria and participants had to consent to
blinding for glucose values in a range that might
represent possible harm (6). Only women with FPG
!5.8 mmol/l and 2-h PG !11.1 mmol/l remained
blinded for their glucose values throughout the study,
which may have led to a selection of low-risk women
in study sites with high screening rates (3). The
reported GDM prevalence rates from the HAPO study
were based on the blinded proportion of the cohort, and
the rates differed substantially between the study sites
(8.7–23.7%) (22).
The impact of socioeconomic factors for the ethnic
differences in GDM prevalence rates has received scant
attention (4, 11). Body height has been negatively
associated with GDM (23) and may serve as a proxy
for intrauterine and childhood growth in the mothers
and socioeconomic determinants related to stunting
(10, 23). The association between height and GDM
could reﬂect a deleterious impact of fetal or early life
deprivation on glucose metabolism in pregnancy,
captured with the WHO criteria.
For the modiﬁed IADPSG criteria (predominantly
driven by a lower FPG cutoff value), prepregnant BMI
had a substantial effect on the prevalence of GDM. This
could be related to the effect of hepatic insulin resistance
on FPG (24). Furthermore, BMI may underestimate the
adverse effect of obesity in Asians (25). The differential
impact of early and later life exposures for developing
GDM identiﬁed with the WHO and the IADPSG criteria
is profound, and to our knowledge has not been
addressed by others.
Strengths of our study include the population-based
study cohort, the universal screening, high attendance
rate, a multi-ethnic population and minimal loss to
follow-up (4%). Compared with other clinical studies,
we consider a response rate of 74% as rather good
(HAPO study included only 53.5%), especially in a time-
consuming study in which women who do not speak
the majority language are included. Our efforts to adapt
the study methods to the needs of women often excluded
in research protocols and to reduce barriers for
inclusion of illiterate or recently immigrated women
therefore seem to have worked. Ethnic minority women
attending the Child Health Clinics appear to be fairly
representative for healthy women of childbearing age
from these groups (12). Forty percent of the total
population living in this residential area has an ethnic
minority background. However, the ethnic minority
proportion is higher among those in reproductive age as
the immigrant population in Norway is fairly young,
with a few people in the old age group. The proportion
of ethnic minorities in this study was higher than for
Norway as a whole, but we chose this residential area to
improve our knowledge regarding the health of ethnic
minority women and explore the possible differences
compared with our reference population. As our sample
of Western European women seems characteristic for
Table 3 Multiple logistic regression models for the (GDM) groups identiﬁed with the WHO and the modiﬁed (IADPSG) criteria, showing the
impact of ethnic origin on GDM after adjusting for covariates.
Multiple model A Multiple model B Multiple model C
OR (95% CI) P OR (95% CI) P OR (95% CI) P
WHO (nZ99)
Years of maternal age 1.13 (1.08–1.19) !0.001 1.13 (1.08–1.19) !0.001 1.12 (1.06–1.18) !0.001
Body height 0.93 (0.89–0.97) !0.001 0.92 (0.88–0.96) !0.001
BMI prepregnant 1.05 (1.00–1.09) 0.044 1.04 (1.00–1.09) 0.054 1.04 (0.99–1.09) 0.111
Parous R1 2.08 (1.29–3.36) 0.003 2.29 (1.39–3.76) 0.001 2.33 (1.39–3.90) 0.001
!10 years education 1.91 (1.05–3.47) 0.034 1.88 (1.01–3.49) 0.047
First-degree relatives with diabetes 1.89 (1.32–2.71) 0.001
Ethnic origin ref. Western Europe 0.026 0.772 0.771
South Asia 2.24 (1.26–3.97) 0.006 1.18 (0.62–2.27) 0.614 0.76 (0.38–1.55) 0.456
Middle East 2.13 (1.12–4.08) 0.022 1.03 (0.49–2.16) 0.944 0.77 (0.35–1.66) 0.503
Other minorities
a 1.45 (0.77–2.73) 0.244 0.82 (0.41–1.65) 0.580 0.69 (0.33–1.43) 0.314
IADPSG (nZ239)
Years of maternal age 1.03 (1.00–1.07) 0.068 1.04 (1.00–1.08) 0.054 1.03 (0.99–1.07) 0.116
Body height 1.01 (0.98–1.03) 0.641 1.00 (0.98–1.03) 0.746
BMI prepregnant 1.10 (1.06–1.13) !0.001 1.09 (1.06–1.13) !0.001 1.09 (1.05–1.13) !0.001
Parous R1 1.17 (0.82–1.65) 0.390 1.21 (0.85–1.73) 0.281 1.15 (0.81–1.64) 0.438
!10 years education 1.50 (0.96–2.36) 0.078 1.55 (0.98–2.45) 0.062
First-degree relatives with diabetes 1.10 (0.83–1.47) 0.510
Ethnic origin ref. Western Europe !0.001 !0.001 0.002
South Asia 2.94 (1.94–4.47) !0.001 2.93 (1.84–4.67) !0.001 2.54 (1.56–4.13) !0.001
Middle East 1.79 (1.10–2.93) 0.019 1.58 (0.92–2.73) 0.100 1.44 (0.83–2.51) 0.196
Other minorities
a 1.44 (0.91–2.28) 0.120 1.35 (0.82–2.21) 0.234 1.25 (0.76–2.06) 0.381
aIncludes Eastern Europe, East Asia, Somalia and sub-Saharan Africa/South America.
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fairly representative for the largest ethnic groups
included in the study. Migration is a global phenomenon
and similar ethnic groups live in many countries, which
make the results relevant outside the Norwegian
context.
Limitations of the study include the relatively small
numbers in some ethnic minority groups and the
absence of 1-h PG measurements, as the study was
conducted before the IADPSG criteria were published.
With the availability of 1-h PG values, the true IADPSG
prevalence rates may have been even higher.
To facilitate participation for universal OGTT
screening, the OGTT was performed in the primary
care setting usually responsible for antenatal care for
normal pregnancies in Norway (13). We used venous
EDTA samples analyzed within 5 min by HemoCue, a
method authorized by the FDA (Department of Health
and Human Services, USA, 2002) for diagnosing
diabetes and used in epidemiological research (26).
This made it possible with an on-site diagnosis of GDM
for clinical care. The comparison with the measure-
ments obtained at the hospital laboratory revealed that
preanalytical glucose consumption was not completely
eliminated despite short transport time. Unfortunately,
we were not able to use glycolytic inhibitors that
may reduce preanalytical glucose consumption, as the
automated central laboratory procedures did not accept
this. However, even the use of standard inhibitors like
sodium ﬂuoride, available in commercially marketed
sample tubes, does not eliminate preanalytical glucose
consumption (27, 28).
Implications for public health
The IADPSG represents a welcome initiative to achieve
internationally accepted criteria for the diagnosis of
GDM. We agree to the principle of an initial screening
test early in pregnancy to identify women with
undiagnosed pregestational diabetes, followed by uni-
versal screening by a standard OGTT later in pregnancy
(5, 29). However, lowering of the diagnostic threshold
for FPG as suggested will have a major effect on the
numbers diagnosed and increase the workload on
the health care system (8). It also raises concern about
the consequences of labeling a large number of women,
based on a test with poor reproducibility (18, 30, 31).
Positive short-time effects from intervention studies
on GDM are observed (32, 33), but only a marginal
effect on the prevalence of macrosomia can be expected
(30), and follow-up data of offspring are so far not
convincing (34, 35). This may indicate that the window
of opportunity to prevent long-term predisposition to
obesity is earlier in fetal life than the currently
recommended time of screening for GDM (36, 37).
Population-based strategies to prevent becoming over-
weight and improve the living conditions in early life
seem to be increasingly important (37, 38).
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